re: Ann: Patrys to Initiate Clinical Trial wi... This is all just speculation, but we know Amgen paid over $10 billion for Onyx, largely on the strength of their one MM drug.
PAB has maybe 520 million shares issued? (Correct me if wrong.)
Even at $1 per share it's only valued at just over half a billion. With a deep pipeline, good patent protection and low toxicity I would have thought it should be valued at more than that (in the long term).
Anyone agree/disagree?
Fat Harry's Cat
Ann: Patrys to Initiate Clinical Trial with Onyx , page-5
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4383931 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1851793 | 5 |
View Market Depth
| Last trade - 11.02am 10/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable